Exact Sciences stock highlights USD 3.247 billion in 2025 sales

Published on 10/05/2026 at 21:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Exact Sciences generated USD 3.247 billion in 2025 sales across screening and precision oncology. Cologuard and Oncotype DX now sit inside Abbott's cancer diagnostics business.

Extreme Makroaufnahme fluoreszierender DNA-Banden im Gelelektrophorese-Gel von Exact Sciences — Exact Sciences Corp. nutzt DNA-Gelelektrophorese für präzise Krebsdiagnostik gezeigt in extremer Makroaufnahme US30063P1057, Illustration mit AI erstellt.

Exact Sciences (ISIN US30063P1057) stock is defined by USD 3.247 billion in 2025 revenue and an ownership change that moved its cancer diagnostics business into Abbott. AInvest reported that revenue increased 18 percent in fiscal year 2025.

Revenue reached USD 3.247 billion

The 2025 figure covers Exact Sciences' screening and precision-oncology operations before the Abbott transaction. Screening generated USD 2.53 billion, while precision oncology contributed USD 717 million, according to AInvest.

The revenue base gives the transaction a clear operating scale: the company produced USD 3.247 billion in 2025 sales while Abbott agreed to an equity deal valued at USD 21 billion. The comparison shows why Cologuard, Oncotype DX and newer cancer-screening products became strategic assets for a larger healthcare group.

Abbott now owns the business

Abbott completed the acquisition on March 23, 2026, and each Exact Sciences common share converted into USD 105.00 in cash. StockTitan reported that Exact Sciences became a wholly owned Abbott subsidiary focused on cancer screening and diagnostics.

The transaction also changed the status of the stock itself. The same StockTitan filing summary identifies March 20, 2026, as Exact Sciences' last trading day on Nasdaq.

Cancer diagnostics grows inside Abbott

Abbott's second-quarter 2026 report placed the acquired operations in its Cancer Diagnostics business. Cancer Diagnostics sales reached USD 919 million in the quarter, with comparable growth of 13.3 percent, according to Trivano.

Exact Sciences operates inside Abbott

Exact Sciences no longer has an independent Nasdaq quotation. Its measurable operating footprint is now reflected through Abbott's Cancer Diagnostics results, while the USD 105.00 cash consideration marks the final share value from the March 23, 2026 transaction.